Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant intermediate-fraction radiotherapy plus epirubicin + ifosfamide for stage II–III soft tissue sarcoma
ChiCTR2600124917Phase 2Completed
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- May 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epirubicin and ifosfamide in soft tissue sarcoma (STS), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Major pathological response rate. Started May 2026; status: completed.
02
Drugs
epirubicinifosfamide
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR2600124917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124917.